Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part in clinical research, who fully understand the study, and who are able to sign a consent form and complete all required procedures
• People who are 18 years of age or older at the time of signing the consent form
• People who have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC) — either through established clinical standards (for those with cirrhosis) or through a tissue biopsy (for those without cirrhosis)
• People who have not previously received any systemic (whole-body) treatment for their liver cancer
• People whose liver cancer is classified as Barcelona Clinic Liver Cancer (BCLC) stage C, or BCLC stage B if local treatments are not considered suitable for them (confirm with trial site)
• People who have at least one measurable area of cancer that has been assessed within 4 weeks before starting the study medication, following specific measurement guidelines (RECIST v1.1); this area should not have had prior local treatment, unless it has clearly grown since that treatment
• People who can provide a tumour tissue sample for testing of a protein called PD-L1, if such a sample is available
• People who have had bone-related radiation therapy completed at least 4 weeks before starting the study medication, or a liver biopsy performed at least 1 week before, with any side effects from those procedures having largely resolved
• People whose liver function has been assessed within 7 days before starting the study medication and falls within an acceptable range (Child-Pugh grade A, or grade B with a score of 7 or below)
• People whose general physical ability, as measured by a standard scoring system (ECOG score), is rated 0 or 1 — meaning they are fully active or have only minor limitations — within 7 days before starting the study medication
• People who are expected to live for at least 12 weeks
• People who have adequate blood count and organ function results from laboratory tests

Who may not be able to join:

• People who are known to have certain less common types of liver cancer, including hepatobiliary duct cell carcinoma, mixed cell carcinoma, or fibroblastic layer cell carcinoma
• People who have a history of a condition where the liver fails to remove toxins from the blood (hepatic encephalopathy), or who have had a liver transplant, or who are preparing for or have previously had any organ or bone marrow transplant
• People who have had serious bleeding from the upper digestive tract related to high blood pressure in the liver veins within the past 6 months, or who have certain vein abnormalities in the food pipe or stomach that carry a high bleeding risk, or who are considered by the study doctor to be at high risk of bleeding
• People whose liver cancer has grown into the main branch of the portal vein (a major blood vessel), or has involved the large vein leading to the heart — though people with a blood clot in the main portal vein but with normal blood flow in the opposite branch may still be considered (confirm with trial site)
• People who have brain or spinal cord lining (meningeal) spread of their cancer that is causing symptoms, has not been treated, or is getting worse
• People who have had another cancer diagnosed within the past 2 years, not counting certain early-stage cancers that have been fully treated (such as some skin cancers, early cervical cancer, localised prostate cancer, breast ductal carcinoma in situ, or papillary thyroid cancer)
• People who still need frequent draining (once a month or more) of fluid around the lungs, heart, or abdomen, even after appropriate treatment
• People who have HIV infection
• People who have active tuberculosis
• People who have current or past lung conditions such as interstitial pneumonia, dust-related lung disease, radiation-related lung damage, or drug-related lung damage, or who have severely reduced lung function
• People who have an active or suspected condition where the immune system attacks the body (autoimmune disease) — though people with thyroid conditions managed with hormone replacement, or with controlled type 1 diabetes managed with insulin, may still be considered
• People who have had an active infection requiring antibiotic or antiviral treatment within 14 days before starting the study medication
• People who have had signs of bleeding (such as coughing up blood or abnormal vaginal bleeding) during the screening period, a moderate bleeding event (Grade 2) within the past 3 months, or a serious bleeding event (Grade 3 or higher) within the past 6 months
• People who have a known history of severe allergic reactions to any of the antibody medicines or ingredients used in this study
• People who have previously been treated with immune checkpoint therapies (such as PD-1, PD-L1/2, or CTLA-4 inhibitors), bevacizumab or similar medicines, or anti-TIGIT therapies or related antibody treatments
• People who, in the study doctor's judgement, have any other reason that makes participation in this trial unsuitable

Important: Always verify eligibility with the trial site directly before applying.